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Abstract
Tumor budding scoring guidelines from the International Tumor Budding Consensus Conference (ITBCC) for colo-
rectal cancer propose three groups: BD1 (0–4 buds/0.785 mm2), BD2 (5–9 buds/0.785 mm2), and BD3 (10 or more
buds/0.785 mm2). Here, we investigate whether a fourth scoring category, namely zero buds, may have additional
clinical relevance. The number of tumor buds/0.785 mm2 was scored in 959 cases. Those with zero tumor buds were
considered BD0, while a new BD1 category of 1–4 buds was proposed. Associations of both scoring approaches
with clinicopathological features were analyzed. Conventional ITBCC scoring showed expected associations with
unfavorable histopathological prognostic factors. In total, 111/959 (11.6%) were BD0. A significant difference was
found when BD0 was compared statistically to BD1 (1–4 buds) for pT, TNM, tumor grade, and lymphatic, venous,
and perineural invasion (p < 0.01, all). Tumors with BD0 occur relatively frequently and contribute additional
information on tumor behavior. BD0 should be considered for subsequent ITBCC guidelines.
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Introduction
Tumor budding is an important prognostic factor in the
clinical management of cancer patients [1]. Although
best described in colorectal cancers, evidence indicates
that patients with a variety of different tumor types suffer
from more aggressive disease and worse overall and
disease-free survival in the context of high-grade tumor
budding [1]. The definition of “high-grade” may vary
depending on the clinical endpoint of interest. The
International Tumor Budding Consensus Conference
(ITBCC) guidelines describe three different budding
grades, termed BD1, BD2, and BD3, which consist of
0–4, 5–9, and 10 or more buds in a hotspot of
0.785 mm2, respectively [2]. For pT1 colorectal cancers,
the clinically relevant threshold for identifying patients
who may benefit from a surgical rather than endoscopic
resection is low-risk BD1 versus high-risk BD2 + BD3.
In contrast, to identify patients with high-risk stage II
colorectal cancers, the threshold is greater, namely low-
risk (BD1 + BD2) versus high-risk BD3 [2]. Still an on-
going matter of debate is the necessity for a fourth BD
category in colorectal cancers: BD0. This category would
highlight tumors with complete absence of tumor bud-
ding all together. Not only could BD0 underline an im-
portant clinical subgroup but also would shed light on
the biology of the tumor budding phenotype in general.
The aim of this study was to determine the frequency
and potential clinical relevance of a BD0 (zero
peritumoral buds) category for primary surgically treated
colorectal cancer patients, with the goal to further refine
the current ITBCC grading scheme for tumor budding.
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All patients with primary colorectal cancer diagnosed at the
Institute of Pathology, University of Bern, from 2002 to April
2019 were originally considered. Of those 1873 consecutive
patients, those receiving pre-operative chemoradiotherapy as
well as those with missing tumor budding scores were excluded
from further study, leaving 959 patients. For patients from 2002
to 2016 (n = 261), all H&E slides of the corresponding resection
specimens were re-reviewed by expert pathologists, blinded to
the clinical outcome. Histopathological information for each tu-
mor from 2016 to 2019 (n = 698) was obtained from diagnostic
records, reported by different attending pathologists. This infor-
mation includes patient gender, the histological subtype of the
tumor, the tumor grade, pT, pN, venous (V), lymphatic (L),
perineural invasion (PNI), and the presence of metastasis (clini-
cal or pathological) at the time of first diagnosis. The Klintrup-
Mäkinen score is also given, which indicates the degree of
peritumoral inflammation on H&E slides and is shown to be a
reproducible and stage-independent prognostic factor [3]. As per
the ITBCC criteria, each case was assigned a budding count,
referring to the total number of buds identified in the densest
0.785 mm2 area and subsequently categorized into BD1 (0–4
buds), BD2 (5–9 buds), and BD3 (10 or more buds) [2]. In order
to determine the added value of a zero-budding category, we
performed a second categorization. Here, we further classify
cases with zero tumor buds (BD0) followed by tumors with 1–
4 tumor buds, denoted as BD1* in this manuscript. BD2 and
BD3 remain the same. Representative images of BD categories
can be found in Fig. 1. Only patients with ITBCC scores were
included in the final analysis, leaving 959 patients. All data are
summarized in Table 1.
Statistical analysis
We used a chi-square test to determine differences in budding
categories in association with categorical data. Two analyses
were performed each time, one analyzing differences in the dis-
tribution of features across BD1–BD3 (grouping BD0 together
with BD1) and analyzing differences only between BD0 and
BD1 to determine the additional value of this extended category.
p values <0.05 were considered statistically significant. Kaplan-
Meier curves and log-rank test were used to test for differences in
survival times by BD category. Analyses were carried out using
SAS (v9.4 The SAS Institute, Cary NC).
Ethics
This study was approved by the ethics committee of the
Canton of Bern KEK 2020–00498.
Results
Validation of ITBCC scores
Analysis of standard ITBCC BD1-BD3 indicated a very
strong relationship between higher BD score and more
Fig. 1 Representative H&E images of 1) BD0, 2) BD1, 3) BD2, and 4) BD3 tumor budding scores in colorectal cancer (×20 objective magnification)
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advanced pT stage, lymph node metastasis, distant me-
tastasis, higher tumor grade, lymphatic and venous ves-
sel invasion, and perineural invasion (all p < 0.0001).
Some differences between budding and Klintrup-
Mäkinen score were identified, but did not show a con-
sistent directionality. These results validate previous
findings from the literature and support the appropriate-
ness of the cohort.
Added value of BD0
Of 959 patients, 111 (11.6%) were found to have BD0 can-
cers. The addition of BD category further strengthened the
association between pT stage and tumor budding (Fig. 2),
showing that 46.3% of pT1 cases were BD0, in contrast to
16.6%, 6.8%, and 5.7% of BD1, BD2, and BD3 cases
(p < 0.0001). Furthermore, 34.6% of patients with BD0
Table 1 Patient characteristics and association of budding score with clinicopathological data (n = 959). BD0 = zero tumor buds, BD1* indicates 1–4
tumor buds, BD2 represent 5–9 buds, and BD3 are 10 buds or more
BD








p value p value for
difference BD0
and BD1*
Gender Male 556 (58.0) 59 (53.2) 202 (56.4) 140 (62.5) 155 (58.5) 0.3470 0.5444
Female 403 (42.0) 52 (46.9) 156 (43.6) 84 (37.5) 110 (41.6)
Histological subtype Adenocarcinoma 855 (89.3) 96 (87.3) 311 (87.1) 205 (91.5) 242 (91.3) 0.0659 0.438
Mucinous 87 (9.1) 14 (12.7) 41 (11.5) 16 (7.1) 16 (6.0)
Other 15 (1.6) 0 (0.0) 5 (1.4) 3 (1.3) 7 (2.6)
Tumor location Left 423 (45.9) 49 (48.5) 157 (44.9) 105 (49.1) 111 (43.2) 0.6663 0.483
Rectum 142 (15.4) 14 (13.9) 54 (15.4) 34 (15.9) 40 (15.6)
Right 357 (51.3) 36 (35.6) 136 (38.9) 74 (34.6) 105 (40.9)
pT pT1 139 (14.6) 50 (46.3) 59 (16.6) 15 (6.8) 15 (5.7) <0.0001 <0.0001
pT2 132 (13.9) 21 (19.4) 65 (18.3) 22 (9.9) 24 (9.1)
pT3 440 (46.2) 30 (27.8) 177 (49.7) 126 (56.8) 107 (40.4)
pT4 241 (25.3) 7 (6.5) 55 (15.5) 59 (26.6) 119 (44.9)
pN pN0 497 (55.7) 75 (84.3) 239 (72.2) 107 (50.5) 75 (29.0) <0.0001 0.065
pN1+2 395 (44.3) 14 (15.7) 91 (21.8) 105 (49.5) 184 (71.0)
pM or cM Absent 274 (77.4) 32 (91.4) 100 (90.1) 74 (81.3) 68 (58.6) <0.0001 0.815
Present 80 (22.6) 3 (8.6) 11 (9.9) 17 (18.7) 48 (41.4)
TNM stage I 112 (18.3) 25 (48.1) 51 (22.9) 21 (14.2) 15 (8.0) <0.0001 0.0026
II 201 (32.9) 14 (26.9) 102 (45.7) 52 (35.1) 33 (17.7)
III 206 (33.7) 10 (19.2) 58 (26.0) 58 (39.2) 80 (42.8)
IV 92 (15.1) 3 (5.8) 12 (5.4) 17 (11.5) 59 (31.6)
Tumor grade G1 106 (11.3) 37 (34.6) 45 (13.0) 18 (8.2) 6 (2.3) <0.0001 <0.0001
G2 656 (70.1) 50 (46.7) 247 (71.2) 169 (76.8) 189 (72.4)
G3 174 (18.6) 20 (18.7) 55 (15.9) 33 (15.0) 66 (25.3)
Lymphatic L0 452 (47.3) 91 (82.7) 234 (65.6) 81 (36.5) 46 (17.4) <0.0001 0.0006
L1 503 (52.7) 19 (17.3) 123 (34.5) 141 (63.5) 219 (82.6)
Venous V0 533 (55.8) 97 (87.4) 241 (67.5) 106 (47.8) 89 (33.6) <0.0001 <0.0001
V1 423 (44.3) 14 (12.6) 116 (32.5) 116 (52.3) 176 (66.4)
Perineural Pn0 769 (81.0) 109 (99.1) 325 (91.8) 177 (80.1) 157 (59.5) <0.0001 0.0067
Pn1 181 (19.1) 1 (0.9) 29 (8.2) 44 (19.9) 107 (40.5)
MMR Deficient 100 (15.5) 12 (17.7) 43 (18.1) 19 (12.2) 26 (14.3) 0.3847 0.9252
Proficient 544 (84.5) 56 (82.4) 194 (81.9) 137 (87.8) 156 (85.7)
Klintrup-Mäkinen
0 32 (3.3) 4 (3.6) 10 (2.8) 2 (0.9) 16 (6.0)
1 448 (46.7) 55 (49.6) 159 (44.4) 109 (48.7) 125 (47.0) 0.009 0.075
2 330 (34.4) 39 (35.1) 119 (33.2) 74 (33.0) 98 (36.8)
3 149 (15.5) 13 (11.7) 70 (19.6) 39 (17.4) 27 (10.2)
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tumors had low-grade tumors, in comparison to 13%, 8.2%,
and 2.3% of BD1, BD2, and BD3 tumors (p < 0.0001).
Similar results were found for lymphatic and venous invasion
as well as perineural invasion (p < 0.01). Of the 139 pT1
cases, information (N0 or N1–2) on lymph node metastasis
was present in 86 patients. Seventy-seven (89.5%) had no
lymph node metastasis. Of the 9 remaining cases, 2 were
BD0 in comparison to 7 with BD1*, BD2, and BD3 tumors.
This difference was, however, not statistically significant (p =
0.4406).
Overall (OS) and disease-free (DFS) survival
information
OS and DFS were available for 361 and 351 patients, respec-
tively, of which only 37 were BD0. Although tumor budding
scores stratify patients into better or worse OS (p = 0.0035)
and DFS (p = 0.0086), there was no significant difference be-
tween BD0 and BD1*.
Discussion
The novel findings of this study show that >10% of all pri-
marily surgically treated colorectal cancers have a complete
absence of tumor budding and that these “BD0” cancers are
far less aggressive than those with even a minimal number of
tumor buds (1–4 tumor buds/0.785 mm2).
The phenomenon of tumor budding cannot be defined as a
“categorical variable.” Some reports in adenocarcinomas (i.e.,
not signet ring cell histology) suggest the number of buds can
range from zero to several hundred depending on the objective
lens area [4]. Although it can be argued that a very large
amount of tumor buds per defined area may be the result of
cutting artifact, the absence of tumor buds along the entire
border of the cancer can be explained by either [1] buds were
overseen during diagnosis or [2] it is the result of a true pattern
of tumor growth, or [3] in the case of pT1, tissues rather
represented pseudoinvasion, which is excluded here, after
careful re-examination of pT1 BD0. The reason for this
growth pattern cannot solely be explained by the presence of
peritumoral lymphocytic inflammation, which is described in
our study by a high Klintrup-Mäkinen score, with values of 3
indicating thick bands of inflammatory infiltrates around the
invasion edge of the cancer [3]. Previous works have shown
that colorectal cancers with more “infiltrating” growth pat-
terns are often high-grade budders and have little in terms of
inflammation [5–7]. In contrast, those with pushing margins
tend to have low budding and are much more heavily in-
flamed. In this study, we find that tumors with absence of
budding (BD0) are independent of Klintrup-Mäkinen scores.
Moreover, these tumors are not more likely to be MSI-H,
which is characterized typically by a high number of
intraepithelial T-lymphocytes. In fact, in contrast to previous
works [8], the relationship between tumor budding and MSI-
H here cannot be confirmed. This result is supported by work
from other groups showing no difference inMSI status [9, 10].
Fig. 2 Distribution of BD0 category across (left upper) pT classification, (right upper) lymphatic vessel invasion, (bottom left) tumor grade, and (bottom
right) venous vessel invasion
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Finally, although mucinous cancers have a more pushing tu-
mor growth pattern, our findings again underline no relation-
ship between budding and histological subtype. A previous
work by our group has also shown that no changes in driver
mutations can explain the presence of tumor budding [11].
Evidence from the tumor stroma points to epigenetic changes
favoring the budding process, for example, methylation of
TWIST1 and TWIST2 in stromal cells, or changes in
miRNA has been found to occur in non-tumor budding re-
gions. Evaluating the expression of MiR-21 in tumor buds,
Moller and colleagues hypothesize that miR-21 expression
may protect fibroblasts, among other cells from cell death,
again underlining an interplay between budding and stroma
[12]. In fact, several reports now also suggest the correlation
between the presence of particular myxoid/immature stroma
and the presence of tumor budding [13, 14]. We therefore
hypothesize that the tumor stroma plays an important role in
the tumor budding phenotype. Studies investigating the inter-
action between tumor buds and the surrounding microenvi-
ronment as well as the composition of a budding-promoting
stroma are warranted.
A category BD0 contributes additional information on tu-
mor behavior. Our results support previous findings, where
statistical models are used to determine the probability of tu-
mor budding counts with lymph node and distant metastasis as
endpoints, underlining the additive effect of single tumor bud-
ding counts in a continuous manner [15]. A tumor with BD0 is
significantly more likely to be pT1 compared to BD1 cancers
(46.3% versus 16.6%) and consequently are of earlier TNM
stage. Conversely, of the 139 pT1 tumors in our series, 62%
are BD0. A complete absence of tumor budding is also more
frequently found in well-differentiated cancers and have less
vessel invasion.
Despite the large sample size of the original cohort (n =
959), a subgroup analysis of pT1 cancers results in low num-
bers of cases (n = 86), of which only 9 present with lymph
node metastasis. The contribution of BD0 or a new 4-tier
system for budding scores with relation to clinical impact in
pT1 cases cannot be confirmed. Our preliminary results show-
ing a high number of BD0 cases in pT1 tumors warrants fur-
ther analysis in a larger pT1 cohort. In addition, overall and
disease-free survival information was available for more than
350 patients in this study, but again only 37 patients have a
BD0 score, which limits us from drawing conclusions related
to patient outcome. Follow-up information for the remaining
patients is still short.
On the other hand, the sample size and mixed cohort allows
us to study associations of BD0 with histopathological fea-
tures. It is a retrospective and prospective collection of ITBCC
scores and data obtained from a real-life diagnostic setting
with numerous reporting pathologists. To conclude, the results
of the study suggest that the addition of a “BD0” category to
the ITBCC scores has value. It occurs relatively frequently,
and is indicative of significantly less aggressive colorectal
cancer compared to those with any degree of tumor budding.
BD0 should be considered for inclusion in subsequent ITBCC
guidelines.
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